Clazosentan

Drug Profile

Clazosentan

Alternative Names: ACT-108475; AXV 034; AXV 034343; Pivlaz

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical; Roche
  • Developer Idorsia Pharmaceuticals
  • Class Anti-ischaemics; Dioxanes; Neuroprotectants; Pyridines; Pyrimidines; Small molecules; Sulfonamides; Tetrazoles
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebral vasospasm
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cerebral vasospasm

Most Recent Events

  • 03 Aug 2017 Actelion Pharmaceuticals completes a phase II trial for Cerebral vasospasm in Japan and South Korea (IV, Infusion) (JapicCTI-152889)
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 16 Jun 2017 Actelion Pharmaceuticals spun off its drug discovery operations and early-stage clinical development assets into a newly created company, Idorsia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top